Intensity Therapeutics, Inc

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. Intensity is based in Westport, Connecticut. For more...

Biopharmaceuticals,pharmaceuticals,interventional radiology,cancer immune therapy,immunotherapy,and health and medicine

Intensity therapeutics, inc operates in the Pharmaceutical manufacturing industry.

Intensity therapeutics, inc's revenue is 11m - 100m

Intensity therapeutics, inc has 11 - 50 employees.